Addyi was initially authorized with the FDA in August 2015 to treat hypoactive sexual need ailment (HSDD) in premenopausal Females. Which is just another way of saying it boosts intercourse travel (also called libido) in women who may have not arrived at menopause. It was the primary such drug accepted for this use.Emergency contraceptive supplemen